首页> 外文期刊>Endocrine. >BRAFV600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay
【24h】

BRAFV600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay

机译:通过焦磷酸测序对并发桥本甲状腺炎的甲状腺结节细针穿刺进行BRAFV600E评估是一种可靠的方法

获取原文
获取原文并翻译 | 示例
           

摘要

Detection of BRAF mutation in cytology specimens has been proposed as a diagnostic adjunct!ve tool in evaluation of thyroid nodules with indeterminate cytology findings. Concurrent papillary thyroid carcinoma and Hashimoto's thyroiditis (HT), a disease characterized by thyroid lymphocytic infiltration, is a frequent occurrence. A large lymphocytic infiltrate might reduce the sensitivity of methods employed to detect BRAF mutation in thyroid cytology specimens. To determine whether testing for BRAF mutational status in fine needle aspirates (FNA) is reliable also in the presence of HT lymphocytic infiltration, we assessed the BRAF status by direct sequencing and pyrosequencing in a series of FNAs with and without concomitant HT lymphocytic infiltration. We also performed the same assessment by pyrosequencing in the corresponding tissue samples. Pyrosequencing demonstrated to be more sensitive than direct sequencing. The percentage of mutant BRAFv600E alleles was higher in FNAs than in the corresponding tissues, probably because of the lower stromal contamination in FNA than in the sections. In the presence of lymphocytic infiltration, the percentage of mutant BRAFv600E alleles determined by pyrosequencing was higher in FNAs than in the corresponding tissue samples (P < 0.0001), indicating a minor lymphocytic contamination in FNA. The diagnostic value of BRAFv600E in inconclusive FNAs was not hampered by thyroid lymphocytic infiltration. These results indicate that BRAFv600E assessment by pyrosequencing is a reliable assay useful to refine inconclusive cytology of thyroid nodules also in the presence of concurrent HT.
机译:已经提出了在细胞学标本中检测BRAF突变作为辅助诊断工具,用于评估具有不确定细胞学发现的甲状腺结节。并发乳头状甲状腺癌和桥本甲状腺炎(HT)是一种以甲状腺淋巴细胞浸润为特征的疾病,这种情况很常见。大量淋巴细胞浸润可能会降低用于检测甲状腺细胞学标本中BRAF突变的方法的敏感性。为了确定在存在HT淋巴细胞浸润的情况下对细针抽吸物(FNA)中的BRAF突变状态进行测试是否可靠,我们通过在具有和不伴有HT淋巴细胞浸润的一系列FNA中通过直接测序和焦磷酸测序来评估BRAF状态。我们还通过在相应的组织样本中进行焦磷酸测序进行了相同的评估。焦磷酸测序比直接测序更敏感。 FNA中突变的BRAFv600E等位基因的百分比高于相应的组织,这可能是因为FNA中的基质污染比切片中的低。在存在淋巴细胞浸润的情况下,通过焦磷酸测序测定的突变BRAFv600E等位基因在FNA中的比例高于相应的组织样本中的比例(P <0.0001),表明FNA中存在少量的淋巴细胞污染。 BRAFv600E在不确定的FNA中的诊断价值不受甲状腺淋巴细胞浸润的影响。这些结果表明,通过焦磷酸测序进行的BRAFv600E评估是一种可靠的测定方法,可用于在存在并发HT的情况下改善甲状腺结节的不确定细胞学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号